Phase 4 N=34 Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
IgA Nephropathy
Primary: Change in Proteinuria at 12 Months — 3; 3; 1; 2 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=76 Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
IGA Nephropathy
Primary: Mean Change of Proteinuria as Measured by Spot Urine Protein/Creatinine Ratio (sPCR) at Week 24 — -157.5; -577.2; -177.4 mg/g — p=0.97
Phase 3 N=20 Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Progressive IgA Nephropathy · Proteinuria
Primary: Number of Subjects With a Complete or Partial Response to Treatment — 8 Participants
Phase 3 N=364 Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
Primary IgA Nephropathy
Primary: Part A: Ratio of Urine Protein to Creatinine Ratio (UPCR) at 9 Months Compared to Baseline — 0.69; 0.95 ratio — p=0.0003
Phase 2 N=155 Safety and Efficacy Study of VIS649 for IgA Nephropathy
Immunoglobulin A Nephropathy · Glomerular Disease · IgAN
Primary: Number of Participants With Adverse Events Graded by Severity — 19; 22; 22; 23 Participants
Phase 2 N=54 Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
Immunoglobulin A (IgA) Nephropathy
Primary: Part 1: Relative Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) in 24-hour Urine at Month 9 — -24.7; -16.5; -30.6; -38.5 gram per gram (g/g) — p=0.6837
N/A N=40 A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
IgA Nephropathy
Primary: Change in Renal Function as Measured With eGFR — 68.9; 73.2 eGFR(min/ml)
Phase 2 N=14 A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy
Glomerulonephritis, Membranous
Primary: Change From Baseline in Proteinuria Levels at Week 28 — 0.7552 Ratio
Phase 4 N=11 Pilot Study of Velcade® in IgA Nephropathy
Chronic Kidney Disease · IgA Nephropathy
Primary: Proteinuria — 2.52; 1.43 grams per 24 hrs
Phase 4 N=16 Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
Kidney Diseases
Primary: 24 Hour Proteinuria — 3.6; 3.8; 2.2; 3.0 g/day
Phase 2 N=46 Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
IgA Nephropathy
Primary: MCP-Mod Estimates of the Ratio to Baseline of Urine Protein to Creatinine Ratio (UPCR) (g/Mol) - Parts 1 and 2 at Day 90 — 0.85; 0.80; 0.76; 0.69 Ratio to baseline…
Phase 2 N=7 Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade
Immunoglobulin A Nephropathy
Primary: Change in Slope of First Morning Urinary PCR From the 8-week RAAS Blocker run-in Period to the 12-week CCX168 Treatment Period — -2.4; 15.3; -23.9 mg/g/week — p=0.965
Phase 2 N=21 Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
IgA Nephropathy · Lupus Nephritis · Membranous Nephropathy
Primary: Part A: Change From Baseline in Proteinuria at Week 48 — -0.1364; 0.3560; 0.3430; -2.0347 ratio
Phase 3 N=119 Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)
Primary IgA Nephropathy
Primary: Ratio of Urine Protein to Creatine Ratio (UPCR) at 9 Months Compared to Baseline — 0.67; 0.69 ratio
Phase 2 N=15 Permeability Factor in Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis
Primary: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. — 0; 0; 0.5; 0.25 proportion of participants with…
Phase 2 N=48 A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
Immunoglobulin A Nephropathy
Primary: Change in Urine Albumin-creatinine Ratio (UA/C) at Week 24 — -55.78 percent change
N/A N=133 Immunoglobulin Levels and Occurrence of Infections After Lung Transplantation and Impact of IgG Replacement
Infections After Lung Transplant
Primary: The Primary Outcome Will be the Total Number of Days With Pneumonia. — 1714; 51 Number of days
Phase 2 N=12 Daratumumab in Treatment of PGNMID and C3 GN
Membranoproliferative Glomerulonephritis
Primary: Number of Treatment-Emergent Adverse Events — 5 Serious Adverse Events
Phase 2 N=9 Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins
Multiple System Atrophy
Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events
Phase 2 N=10 Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction
Multiple Myeloma · Plasma Cell Neoplasm
Primary: Tolerance for Human Immune Globulin Intravenous (IGIV), as Reflected by the Number and Severity of Toxicity Incidents Occurring in Ten Patients Receiving at Least One…
Phase 3 N=6 Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy
Autoimmune Autonomic Ganglionopathy (AAG)
Primary: Change in Systolic Blood Pressure During 60° Tilt (ΔSBP) — 42.5; -12.3 mmHg
Phase 3 N=34 GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study
Alpha1-antitrypsin Deficiency
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Potentially Related to Presence of Particle Load in the GLASSIA Solution — 0; 0 Participants
Phase 3 N=39 Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy
Glomerulonephritis, Membranous
Primary: Percentage of Complete Remission — 4; 3 Participants
Phase 2 N=10 Zanubrutinib in Patients With IgG4-Related Disease
IgG4 Related Disease
Primary: Volume of the Submandibular Glands on PET-MRI — 12.7; 9.34; -3.37 cm^3 — p=< 0.001
Phase 2 N=11 Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
Fibrillary Glomerulonephritis
Primary: Change in 24 Hour Creatinine Clearance — 41.0 mL/min/SA — p=0.072
Phase 2 N=20 Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
Wegener's Granulomatosis
Primary: Safety of Abatacept - Number of Participants With Adverse Events — 7; 16; 14; 1 participants
Phase 2 N=11 Intravenous Immunoglobulin (IVIG) in Lung Transplantation
Hypogammaglobulinemia · Lung Transplantation
Primary: Number of Clinically Diagnosed Bacterial Infections During the Treatment Period — 3; 1 Infections
Phase 2 N=15 Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease
Anti-Glomerular Basement Membrane Antibody Disease
Primary: Number of Patients With Independent Renal Function at 6 Months — 5; 5; 10 Participants
Phase 2 N=8 Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney Disease
Chronic Kidney Disease
Primary: Efficacy — 372 MFI
N/A N=60 Auto-antibodies Prevalence and CD1 Role in Gaucher Disease
Gaucher Disease
Primary: Number of Patients With GD Diagnosis Confirmed by : Enzyme Testing of acidβ-glucosidase Activity Activity <15% in Blood Leucocytes Completed When Necsssary by GB1…